Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
      Description

      This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.

      Conditions
      Advanced Malignant Solid NeoplasmRecurrent Ependymal TumorRecurrent Ewing SarcomaRecurrent GliomaRecurrent HepatoblastomaRecurrent Histiocytic and Dendritic Cell NeoplasmRecurrent Langerhans Cell HistiocytosisRecurrent Malignant Germ Cell TumorRecurrent Malignant Solid NeoplasmRecurrent MedulloblastomaRecurrent NeuroblastomaRecurrent Non-Hodgkin LymphomaRecurrent OsteosarcomaRecurrent Peripheral Primitive Neuroectodermal TumorRecurrent Primary Malignant Central Nervous System NeoplasmRecurrent Rhabdoid TumorRecurrent RhabdomyosarcomaRecurrent Soft Tissue SarcomaRefractory EpendymomaRefractory Ewing SarcomaRefractory GliomaRefractory HepatoblastomaRefractory Histiocytic and Dendritic Cell NeoplasmRefractory Langerhans Cell HistiocytosisRefractory Malignant Germ Cell TumorRefractory Malignant Solid NeoplasmRefractory MedulloblastomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Primary Malignant Central Nervous System NeoplasmRefractory Rhabdoid TumorRefractory RhabdomyosarcomaRefractory Soft Tissue SarcomaWilms Tumor
      Talk to us